Abivax cancer risk framed as mispriced overhang
The speakers argued that market concerns around a cancer signal in Abivax's ulcerative colitis trial are unfounded, creating a severe valuation disconnect ahead of upcoming safety data and potential M&A.
Sign in to read the full idea
The argument, what validates it, the risks discussed and hearing it from the source are for signed-in members. Free accounts read 3 ideas in full a day. No card required.